Epidermal Growth Factor Receptor-targeted Gelatin-based Engineered Nanocarriers for DNA Delivery and Transfection in Human Pancreatic Cancer Cells

Overview

Journal AAPS J

Specialty Pharmacology

Date 2008 Nov 27

PMID 19034673

Citations 16

Authors

Padmaja Magadala

Mansoor Amiji

Affiliations

Soon will be listed here.

Abstract

Type B gelatin-based engineered nanocarrier systems (GENS) have been used over the last several years as a non-condensing systemic and oral DNA delivery system. In this study, we have modified the surface of GENS with epidermal growth factor receptor (EGFR)-targeting peptide for gene delivery and transfection in pancreatic cancer cell lines. GENS were prepared by the solvent displacement method and the EGFR-targeting peptide was grafted on the surface using a hetero-bifunctional poly(ethylene glycol) (PEG) spacer. Plasmid DNA, encoding for enhanced green fluorescent protein (GFP), was efficiently encapsulated and protected from degrading enzymes in the control and surface-modified GENS. Upon incubation with EGFR over-expressing Panc-1 human pancreatic adenocarcinoma cells, the peptide-modified nanoparticles were found to be internalized efficiently by receptor-mediated endocytosis. Both quantitative and qualitative transgene expression efficiencies were significantly enhanced when plasmid DNA was administered with EGFR-targeted GENS relative to the control-unmodified gelatin or PEG-modified gelatin nanoparticle systems. Based on these preliminary results, EGFR-targeted GENS show tremendous promise as a safe and effective gene delivery vector with the potential to treat pancreatic cancer.

Citing Articles

Gelatin as It Is: History and Modernity.

Mikhailov O Int J Mol Sci. 2023; 24(4).

PMID: 36834993 PMC: 9963746. DOI: 10.3390/ijms24043583.

Nature-Based Biomaterials and Their Application in Biomedicine.

Troy E, Tilbury M, Power A, Wall J Polymers (Basel). 2021; 13(19).

PMID: 34641137 PMC: 8513057. DOI: 10.3390/polym13193321.

Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors.

Gagliardi A, Giuliano E, Venkateswararao E, Fresta M, Bulotta S, Awasthi V Front Pharmacol. 2021; 12:601626.

PMID: 33613290 PMC: 7887387. DOI: 10.3389/fphar.2021.601626.

GE11 Peptide as an Active Targeting Agent in Antitumor Therapy: A Minireview.

Genta I, Chiesa E, Colzani B, Modena T, Conti B, Dorati R Pharmaceutics. 2017; 10(1).

PMID: 29271876 PMC: 5874815. DOI: 10.3390/pharmaceutics10010002.

Resveratrol-Loaded Albumin Nanoparticles with Prolonged Blood Circulation and Improved Biocompatibility for Highly Effective Targeted Pancreatic Tumor Therapy.

Geng T, Zhao X, Ma M, Zhu G, Yin L Nanoscale Res Lett. 2017; 12(1):437.

PMID: 28673056 PMC: 5493600. DOI: 10.1186/s11671-017-2206-6.

References

Panyam J, Labhasetwar V . Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003; 55(3):329-47. DOI: 10.1016/s0169-409x(02)00228-4. View

Neves C, Escriou V, Byk G, Scherman D, Wils P . Intracellular fate and nuclear targeting of plasmid DNA. Cell Biol Toxicol. 1999; 15(3):193-202. DOI: 10.1023/a:1007693805849. View

Yamanaka Y, Friess H, Kobrin M, Buchler M, Beger H, Korc M . Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993; 13(3):565-9. View

Roth J . Gene replacement strategies for lung cancer. Curr Opin Oncol. 1998; 10(2):127-32. DOI: 10.1097/00001622-199803000-00008. View

Guillemard V, Nedev H, Berezov A, Murali R, Saragovi H . HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand. DNA Cell Biol. 2005; 24(6):350-8. DOI: 10.1089/dna.2005.24.351. View

Roth J . Adenovirus p53 gene therapy. Expert Opin Biol Ther. 2005; 6(1):55-61. DOI: 10.1517/14712598.6.1.55. View

Tobita K, Kijima H, Dowaki S, Kashiwagi H, Ohtani Y, Oida Y . Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med. 2003; 11(3):305-9. View

Bhavsar M, Amiji M . Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract. AAPS PharmSciTech. 2008; 9(1):288-94. PMC: 2976886. DOI: 10.1208/s12249-007-9021-9. View

Bhavsar M, Amiji M . Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J Control Release. 2007; 119(3):339-48. DOI: 10.1016/j.jconrel.2007.03.006. View

10.

Roth J, Grammer S . Gene replacement therapy for non-small cell lung cancer: a review. Hematol Oncol Clin North Am. 2004; 18(1):215-29. DOI: 10.1016/s0889-8588(03)00144-8. View

11.

Kommareddy S, Amiji M . Poly(ethylene glycol)-modified thiolated gelatin nanoparticles for glutathione-responsive intracellular DNA delivery. Nanomedicine. 2007; 3(1):32-42. PMC: 1885230. DOI: 10.1016/j.nano.2006.11.005. View

12.

Kaul G, Amiji M . Biodistribution and targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model. J Drug Target. 2004; 12(9-10):585-91. PMC: 1242174. DOI: 10.1080/10611860400013451. View

13.

Jacob D, Davis J, Zhang L, Zhu H, Teraishi F, Fang B . Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Ther. 2004; 12(2):109-15. DOI: 10.1038/sj.cgt.7700773. View

14.

Huber B . Gene therapy strategies for treating neoplastic disease. Ann N Y Acad Sci. 1994; 716:6-11; discussion 20-2. DOI: 10.1111/j.1749-6632.1994.tb21699.x. View

15.

Roth J, Grammer S, Swisher S, Komaki R, Nemunaitis J, Merritt J . P53 gene replacement for cancer--interactions with DNA damaging agents. Acta Oncol. 2002; 40(6):739-44. DOI: 10.1080/02841860152619160. View

16.

Roth J . Gene replacement strategies for cancer. Isr J Med Sci. 1996; 32(2):89-94. View

17.

Bhavsar M, Tiwari S, Amiji M . Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J Control Release. 2005; 110(2):422-430. DOI: 10.1016/j.jconrel.2005.11.001. View

18.

Li Z, Zhao R, Wu X, Sun Y, Yao M, Li J . Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 2005; 19(14):1978-85. DOI: 10.1096/fj.05-4058com. View

19.

Kommareddy S, Amiji M . Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione. Bioconjug Chem. 2005; 16(6):1423-32. DOI: 10.1021/bc050146t. View

20.

Jarvinen T, Ruoslahti E . Molecular changes in the vasculature of injured tissues. Am J Pathol. 2007; 171(2):702-11. PMC: 1934529. DOI: 10.2353/ajpath.2007.061251. View